America and Britain Finalize No-Tariff Deal on Drugs.
Britain and America have secured a important bilateral deal that will keep no import taxes on British medicine products being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the public health system. This move ensures that import taxes on these key products will remain at nothing for a period of 36 months.
This deal follows previous threats to dramatically increase import taxes on branded pharmaceutical products, with figures discussed as high as double the cost.
"This agreement between the UK strengthens the global environment for new treatments and introduces much-needed balance to transatlantic medicine commerce," an announcement declared.
Economic Significance
Pharmaceuticals represent one of the Britain's most significant exports to the US, which is easily the primary buyer for large British pharmaceutical firms.
Statistics indicate that in the 12 months prior to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that span.
"This deal protects employment, stimulates funding and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a target to raise total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, rebates exceeded 20%.
Recent Tensions
This agreement follows a ongoing tension between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that US patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.